Improvement in dermatomyositis-associated muscle disease with anifrolumab

Leila H Shayegan^{1

2}, Katharina S Shaw³, Ged G Wieschhoff⁴, Nnenna Ezeh¹, Yoo Jung Kim^{1

2}, Neda Shahriari¹, Ellen E Anshelevich^{1

5}, Lorena A Acevedo^{1

6}, Avery LaChance¹, Fatma Dedeoglu², Rochelle L Castillo¹, Allen W Ho¹, Ruth Ann Vleugels^{1

2}

Affiliations

¹ Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
² Dermatology Program, Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
³ Section of Dermatology, The Children's Hospital of Philadelphia and Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁴ Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁵ Hackensack Meridian School of Medicine, Nutley, NJ, USA.
⁶ University of Puerto Rico, Medical Science Campus, PR, USA.

PMID: 40036364
PMCID: PMC12107708 (available on 2026-05-19)
DOI: 10.1093/bjd/ljaf064

Improvement in dermatomyositis-associated muscle disease with anifrolumab

Leila H Shayegan et al. Br J Dermatol. 2025.

. 2025 May 19;192(6):1126-1128.

doi: 10.1093/bjd/ljaf064.

Authors

Affiliations

¹ Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
² Dermatology Program, Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
³ Section of Dermatology, The Children's Hospital of Philadelphia and Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁴ Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁵ Hackensack Meridian School of Medicine, Nutley, NJ, USA.
⁶ University of Puerto Rico, Medical Science Campus, PR, USA.

PMID: 40036364
PMCID: PMC12107708 (available on 2026-05-19)
DOI: 10.1093/bjd/ljaf064

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: R.A.V. is a consultant for Abbvie, Apogee, AstraZeneca, BMS, Lilly and Priovant. A.L.C. has received research funding from Pfizer and Merck and consulting funds from J&J, MedaCorp, Guidepoint and TD Cowen unrelated to the current manuscript.

References

1. Shaw KS, Reusch DB, Castillo RL, et al. Rapid improvement in recalcitrant cutaneous juvenile dermatomyositis with anifrolumab treatment. JAMA Dermatol 2024; 160(2):237–238. - PubMed
1. Shaw KS, Hashemi KB, Castillo RL, et al. Anifrolumab in recalcitrant cutaneous dermatomyositis: a multicenter retrospective cohort study. J Am Acad Dermatol 2024; S0190–9622(24)02609–4. - PubMed
1. Huang B, Li H, Jiang Q, et al. Elevated type I IFN signalling directly affects CD8+ T-cell distribution and autoantigen recognition of the skeletal muscles in active JDM patients. J Autoimmun 2024; 146:103232. - PubMed
1. Ang PS, Ezenwa E, Ko K, Hoffman MD. Refractory dermatomyositis responsive to anifrolumab. JAAD Case Rep 2023; 43:27–29. - PMC - PubMed
1. Srinivasa Murthy M, Haikal A. A novel treatment for skin manifestations in dermatomyositis: a case report. Cureus 2024; 16(8):e66704. - PMC - PubMed

Grants and funding

K08 AR079007/AR/NIAMS NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Improvement in dermatomyositis-associated muscle disease with anifrolumab

Affiliations

Improvement in dermatomyositis-associated muscle disease with anifrolumab

Authors

Affiliations

Conflict of interest statement

References

Grants and funding

LinkOut - more resources

Full Text Sources